Sign In

Login

Password

Forgot Password ? Sign Up

CD137 (Slovak Wikipedia)

Analysis of information sources in references of the Wikipedia article "CD137" in Slovak language version.

refsWebsite
Global rank Slovak rank
23doi.org
2nd place
7th place
16worldcat.org
5th place
1st place
5elsevier.com
610th place
631st place
4nature.com
234th place
71st place
3immunenetwork.org
low place
low place
2koreascience.or.kr
low place
low place
2frontiersin.org
4,679th place
887th place
1wiley.com
222nd place
174th place
1ahajournals.org
3,608th place
low place
1tandfonline.com
507th place
468th place
1jimmunol.org
low place
9,236th place
1ashpublications.org
low place
low place

ahajournals.org

  • YUAN, Wei; XU, Chong; LI, Bo. Contributions of Costimulatory Molecule CD137 in Endothelial Cells. Journal of the American Heart Association, 2021-06, roč. 10, čís. 11, s. e020721. Dostupné online [cit. 2022-05-24]. ISSN 2047-9980. DOI: 10.1161/JAHA.120.020721. (po anglicky)

ashpublications.org

  • CHESTER, Cariad; SANMAMED, Miguel F.; WANG, Jun. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 2018-01-04, roč. 131, čís. 1, s. 49–57. Dostupné online [cit. 2022-05-27]. ISSN 0006-4971. DOI: 10.1182/blood-2017-06-741041. (po anglicky)

doi.org

dx.doi.org

  • WÖLFL, Matthias; KUBALL, Jürgen; EYRICH, Matthias. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities: CD137 for Detecting Antigen-Specific T-cells. Cytometry Part A, 2008-11, roč. 73A, čís. 11, s. 1043–1049. Dostupné online [cit. 2022-05-24]. DOI: 10.1002/cyto.a.20594. (po anglicky)
  • VINAY, Dass S; KWON, Byoung S. 4-1BB signaling beyond T cells. Cellular & Molecular Immunology, 2011-07, roč. 8, čís. 4, s. 281–284. Dostupné online [cit. 2022-05-24]. ISSN 1672-7681. DOI: 10.1038/cmi.2010.82. (po anglicky)
  • CROFT, Michael. The role of TNF superfamily members in T-cell function and diseases. Nature Reviews Immunology, 2009-04, roč. 9, čís. 4, s. 271–285. Dostupné online [cit. 2022-05-24]. ISSN 1474-1733. DOI: 10.1038/nri2526. (po anglicky)
  • YUAN, Wei; XU, Chong; LI, Bo. Contributions of Costimulatory Molecule CD137 in Endothelial Cells. Journal of the American Heart Association, 2021-06, roč. 10, čís. 11, s. e020721. Dostupné online [cit. 2022-05-24]. ISSN 2047-9980. DOI: 10.1161/JAHA.120.020721. (po anglicky)
  • KWON, Byungsuk. Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?. Immune Network, 2015, roč. 15, čís. 3, s. 121. Dostupné online [cit. 2022-05-25]. ISSN 1598-2629. DOI: 10.4110/in.2015.15.3.121. (po anglicky)
  • ETXEBERRIA, Iñaki; GLEZ-VAZ, Javier; TEIJEIRA, Álvaro. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open, 2019, roč. 4, s. e000733. Dostupné online [cit. 2022-05-27]. DOI: 10.1136/esmoopen-2020-000733. (po anglicky)
  • VINAY, Dass S.; KWON, Byoung S.. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports, 2014-03-31, roč. 47, čís. 3, s. 122–129. Dostupné online [cit. 2022-05-24]. ISSN 1976-6696. DOI: 10.5483/BMBRep.2014.47.3.283. (po anglicky)
  • ETXEBERRIA, Iñaki; GLEZ-VAZ, Javier; TEIJEIRA, Álvaro. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open, 2019, roč. 4, s. e000733. Dostupné online [cit. 2022-05-24]. DOI: 10.1136/esmoopen-2020-000733. (po anglicky)
  • STOLL, A.; BRUNS, H.; FUCHS, M.. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. Leukemia, 2021-12, roč. 35, čís. 12, s. 3482–3496. Dostupné online [cit. 2022-05-24]. ISSN 1476-5551. DOI: 10.1038/s41375-021-01287-1. (po anglicky)
  • VINAY, Dass S.; KWON, Byoung S.. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports, 2014-03-31, roč. 47, čís. 3, s. 122–129. Dostupné online [cit. 2022-05-25]. ISSN 1976-6696. DOI: 10.5483/BMBRep.2014.47.3.283. (po anglicky)
  • KWON, Byungsuk. Regulation of Inflammation by Bidirectional Signaling through CD137 and Its Ligand. Immune Network, 2012, roč. 12, čís. 5, s. 176. Dostupné online [cit. 2022-05-27]. ISSN 1598-2629. DOI: 10.4110/in.2012.12.5.176. (po anglicky)
  • DHARMADHIKARI, Bhushan; WU, Meihui; ABDULLAH, Nur Sharalyn. CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. OncoImmunology, 2016-04-02, roč. 5, čís. 4, s. e1113367. Dostupné online [cit. 2022-05-25]. ISSN 2162-402X. DOI: 10.1080/2162402X.2015.1113367. (po anglicky)
  • COLE, Suzanne L.; BENAM, Kambez H.; MCMICHAEL, Andrew J.. Involvement of the 4-1BB/4-1BBL Pathway in Control of Monocyte Numbers by Invariant NKT Cells. The Journal of Immunology, 2014-04-15, roč. 192, čís. 8, s. 3898–3907. Dostupné online [cit. 2022-05-25]. ISSN 0022-1767. DOI: 10.4049/jimmunol.1302385. (po anglicky)
  • CHESTER, Cariad; AMBULKAR, Siddhant; KOHRT, Holbrook E.. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunology, Immunotherapy, 2016-10-01, roč. 65, čís. 10, s. 1243–1248. Dostupné online [cit. 2022-05-25]. ISSN 1432-0851. DOI: 10.1007/s00262-016-1829-2. (po anglicky)
  • KWON, Byungsuk. Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?. Immune Network, 2015, roč. 15, čís. 3, s. 121. Dostupné online [cit. 2022-05-27]. ISSN 1598-2629. DOI: 10.4110/in.2015.15.3.121. (po anglicky)
  • LI, Yan; TAN, Shuguang; ZHANG, Chang. Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. Cell Reports, 2018-10, roč. 25, čís. 4, s. 909–920.e4. Dostupné online [cit. 2022-05-25]. DOI: 10.1016/j.celrep.2018.09.073. (po anglicky)
  • CHIN, S. Michael; KIMBERLIN, Christopher R.; ROE-ZURZ, Zygy. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nature Communications, 2018-12, roč. 9, čís. 1, s. 4679. Dostupné online [cit. 2022-05-25]. ISSN 2041-1723. DOI: 10.1038/s41467-018-07136-7. (po anglicky)
  • ZAPATA, Juan M.; PEREZ-CHACON, Gema; CARR-BAENA, Pablo. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. Frontiers in Immunology, 2018-11-15, roč. 9, s. 2618. Dostupné online [cit. 2022-05-27]. ISSN 1664-3224. DOI: 10.3389/fimmu.2018.02618.
  • MADIRAJU, Charitha; NOVACK, Jeffrey P.; REED, John C.. K63 ubiquitination in immune signaling. Trends in Immunology, 2022-02, roč. 43, čís. 2, s. 148–162. Dostupné online [cit. 2022-05-27]. DOI: 10.1016/j.it.2021.12.005. (po anglicky)
  • WANG, Luyao; MA, Qingxia; YAO, Ruixue. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. International Immunopharmacology, 2020-02, roč. 79, s. 106088. Dostupné online [cit. 2022-05-27]. DOI: 10.1016/j.intimp.2019.106088. (po anglicky)
  • CHESTER, Cariad; SANMAMED, Miguel F.; WANG, Jun. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 2018-01-04, roč. 131, čís. 1, s. 49–57. Dostupné online [cit. 2022-05-27]. ISSN 0006-4971. DOI: 10.1182/blood-2017-06-741041. (po anglicky)
  • DAI, Qiang; HAN, Ping; QI, Xinyue. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells. Frontiers in Immunology, 2020-11-13, roč. 11, s. 539654. Dostupné online [cit. 2022-05-27]. ISSN 1664-3224. DOI: 10.3389/fimmu.2020.539654.

doi.org

  • CHESTER, Cariad; AMBULKAR, Siddhant; KOHRT, Holbrook E.. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunology, Immunotherapy, 2016-10-01, roč. 65, čís. 10, s. 1243–1248. Dostupné online [cit. 2022-05-25]. ISSN 1432-0851. DOI: 10.1007/s00262-016-1829-2. (po anglicky)

elsevier.com

linkinghub.elsevier.com

  • ETXEBERRIA, Iñaki; GLEZ-VAZ, Javier; TEIJEIRA, Álvaro. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open, 2019, roč. 4, s. e000733. Dostupné online [cit. 2022-05-27]. DOI: 10.1136/esmoopen-2020-000733. (po anglicky)
  • ETXEBERRIA, Iñaki; GLEZ-VAZ, Javier; TEIJEIRA, Álvaro. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open, 2019, roč. 4, s. e000733. Dostupné online [cit. 2022-05-24]. DOI: 10.1136/esmoopen-2020-000733. (po anglicky)
  • LI, Yan; TAN, Shuguang; ZHANG, Chang. Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. Cell Reports, 2018-10, roč. 25, čís. 4, s. 909–920.e4. Dostupné online [cit. 2022-05-25]. DOI: 10.1016/j.celrep.2018.09.073. (po anglicky)
  • MADIRAJU, Charitha; NOVACK, Jeffrey P.; REED, John C.. K63 ubiquitination in immune signaling. Trends in Immunology, 2022-02, roč. 43, čís. 2, s. 148–162. Dostupné online [cit. 2022-05-27]. DOI: 10.1016/j.it.2021.12.005. (po anglicky)
  • WANG, Luyao; MA, Qingxia; YAO, Ruixue. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. International Immunopharmacology, 2020-02, roč. 79, s. 106088. Dostupné online [cit. 2022-05-27]. DOI: 10.1016/j.intimp.2019.106088. (po anglicky)

frontiersin.org

  • ZAPATA, Juan M.; PEREZ-CHACON, Gema; CARR-BAENA, Pablo. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. Frontiers in Immunology, 2018-11-15, roč. 9, s. 2618. Dostupné online [cit. 2022-05-27]. ISSN 1664-3224. DOI: 10.3389/fimmu.2018.02618.
  • DAI, Qiang; HAN, Ping; QI, Xinyue. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells. Frontiers in Immunology, 2020-11-13, roč. 11, s. 539654. Dostupné online [cit. 2022-05-27]. ISSN 1664-3224. DOI: 10.3389/fimmu.2020.539654.

immunenetwork.org

jimmunol.org

  • COLE, Suzanne L.; BENAM, Kambez H.; MCMICHAEL, Andrew J.. Involvement of the 4-1BB/4-1BBL Pathway in Control of Monocyte Numbers by Invariant NKT Cells. The Journal of Immunology, 2014-04-15, roč. 192, čís. 8, s. 3898–3907. Dostupné online [cit. 2022-05-25]. ISSN 0022-1767. DOI: 10.4049/jimmunol.1302385. (po anglicky)

koreascience.or.kr

nature.com

  • VINAY, Dass S; KWON, Byoung S. 4-1BB signaling beyond T cells. Cellular & Molecular Immunology, 2011-07, roč. 8, čís. 4, s. 281–284. Dostupné online [cit. 2022-05-24]. ISSN 1672-7681. DOI: 10.1038/cmi.2010.82. (po anglicky)
  • CROFT, Michael. The role of TNF superfamily members in T-cell function and diseases. Nature Reviews Immunology, 2009-04, roč. 9, čís. 4, s. 271–285. Dostupné online [cit. 2022-05-24]. ISSN 1474-1733. DOI: 10.1038/nri2526. (po anglicky)
  • STOLL, A.; BRUNS, H.; FUCHS, M.. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. Leukemia, 2021-12, roč. 35, čís. 12, s. 3482–3496. Dostupné online [cit. 2022-05-24]. ISSN 1476-5551. DOI: 10.1038/s41375-021-01287-1. (po anglicky)
  • CHIN, S. Michael; KIMBERLIN, Christopher R.; ROE-ZURZ, Zygy. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nature Communications, 2018-12, roč. 9, čís. 1, s. 4679. Dostupné online [cit. 2022-05-25]. ISSN 2041-1723. DOI: 10.1038/s41467-018-07136-7. (po anglicky)

tandfonline.com

  • DHARMADHIKARI, Bhushan; WU, Meihui; ABDULLAH, Nur Sharalyn. CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. OncoImmunology, 2016-04-02, roč. 5, čís. 4, s. e1113367. Dostupné online [cit. 2022-05-25]. ISSN 2162-402X. DOI: 10.1080/2162402X.2015.1113367. (po anglicky)

wiley.com

onlinelibrary.wiley.com

  • WÖLFL, Matthias; KUBALL, Jürgen; EYRICH, Matthias. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities: CD137 for Detecting Antigen-Specific T-cells. Cytometry Part A, 2008-11, roč. 73A, čís. 11, s. 1043–1049. Dostupné online [cit. 2022-05-24]. DOI: 10.1002/cyto.a.20594. (po anglicky)

worldcat.org

  • VINAY, Dass S; KWON, Byoung S. 4-1BB signaling beyond T cells. Cellular & Molecular Immunology, 2011-07, roč. 8, čís. 4, s. 281–284. Dostupné online [cit. 2022-05-24]. ISSN 1672-7681. DOI: 10.1038/cmi.2010.82. (po anglicky)
  • CROFT, Michael. The role of TNF superfamily members in T-cell function and diseases. Nature Reviews Immunology, 2009-04, roč. 9, čís. 4, s. 271–285. Dostupné online [cit. 2022-05-24]. ISSN 1474-1733. DOI: 10.1038/nri2526. (po anglicky)
  • YUAN, Wei; XU, Chong; LI, Bo. Contributions of Costimulatory Molecule CD137 in Endothelial Cells. Journal of the American Heart Association, 2021-06, roč. 10, čís. 11, s. e020721. Dostupné online [cit. 2022-05-24]. ISSN 2047-9980. DOI: 10.1161/JAHA.120.020721. (po anglicky)
  • KWON, Byungsuk. Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?. Immune Network, 2015, roč. 15, čís. 3, s. 121. Dostupné online [cit. 2022-05-25]. ISSN 1598-2629. DOI: 10.4110/in.2015.15.3.121. (po anglicky)
  • VINAY, Dass S.; KWON, Byoung S.. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports, 2014-03-31, roč. 47, čís. 3, s. 122–129. Dostupné online [cit. 2022-05-24]. ISSN 1976-6696. DOI: 10.5483/BMBRep.2014.47.3.283. (po anglicky)
  • STOLL, A.; BRUNS, H.; FUCHS, M.. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. Leukemia, 2021-12, roč. 35, čís. 12, s. 3482–3496. Dostupné online [cit. 2022-05-24]. ISSN 1476-5551. DOI: 10.1038/s41375-021-01287-1. (po anglicky)
  • VINAY, Dass S.; KWON, Byoung S.. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports, 2014-03-31, roč. 47, čís. 3, s. 122–129. Dostupné online [cit. 2022-05-25]. ISSN 1976-6696. DOI: 10.5483/BMBRep.2014.47.3.283. (po anglicky)
  • KWON, Byungsuk. Regulation of Inflammation by Bidirectional Signaling through CD137 and Its Ligand. Immune Network, 2012, roč. 12, čís. 5, s. 176. Dostupné online [cit. 2022-05-27]. ISSN 1598-2629. DOI: 10.4110/in.2012.12.5.176. (po anglicky)
  • DHARMADHIKARI, Bhushan; WU, Meihui; ABDULLAH, Nur Sharalyn. CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. OncoImmunology, 2016-04-02, roč. 5, čís. 4, s. e1113367. Dostupné online [cit. 2022-05-25]. ISSN 2162-402X. DOI: 10.1080/2162402X.2015.1113367. (po anglicky)
  • COLE, Suzanne L.; BENAM, Kambez H.; MCMICHAEL, Andrew J.. Involvement of the 4-1BB/4-1BBL Pathway in Control of Monocyte Numbers by Invariant NKT Cells. The Journal of Immunology, 2014-04-15, roč. 192, čís. 8, s. 3898–3907. Dostupné online [cit. 2022-05-25]. ISSN 0022-1767. DOI: 10.4049/jimmunol.1302385. (po anglicky)
  • CHESTER, Cariad; AMBULKAR, Siddhant; KOHRT, Holbrook E.. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunology, Immunotherapy, 2016-10-01, roč. 65, čís. 10, s. 1243–1248. Dostupné online [cit. 2022-05-25]. ISSN 1432-0851. DOI: 10.1007/s00262-016-1829-2. (po anglicky)
  • KWON, Byungsuk. Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?. Immune Network, 2015, roč. 15, čís. 3, s. 121. Dostupné online [cit. 2022-05-27]. ISSN 1598-2629. DOI: 10.4110/in.2015.15.3.121. (po anglicky)
  • CHIN, S. Michael; KIMBERLIN, Christopher R.; ROE-ZURZ, Zygy. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nature Communications, 2018-12, roč. 9, čís. 1, s. 4679. Dostupné online [cit. 2022-05-25]. ISSN 2041-1723. DOI: 10.1038/s41467-018-07136-7. (po anglicky)
  • ZAPATA, Juan M.; PEREZ-CHACON, Gema; CARR-BAENA, Pablo. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. Frontiers in Immunology, 2018-11-15, roč. 9, s. 2618. Dostupné online [cit. 2022-05-27]. ISSN 1664-3224. DOI: 10.3389/fimmu.2018.02618.
  • CHESTER, Cariad; SANMAMED, Miguel F.; WANG, Jun. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 2018-01-04, roč. 131, čís. 1, s. 49–57. Dostupné online [cit. 2022-05-27]. ISSN 0006-4971. DOI: 10.1182/blood-2017-06-741041. (po anglicky)
  • DAI, Qiang; HAN, Ping; QI, Xinyue. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells. Frontiers in Immunology, 2020-11-13, roč. 11, s. 539654. Dostupné online [cit. 2022-05-27]. ISSN 1664-3224. DOI: 10.3389/fimmu.2020.539654.